Daily Respiratory Research Analysis
Analyzed 231 papers and selected 3 impactful papers.
Summary
Three impactful studies advance respiratory medicine across pathophysiology, therapeutics, and precision stratification. A large randomized trial follow-up shows nerandomilast reduces clinically important outcomes in progressive pulmonary fibrosis, while a pragmatic, near-patient biomarker panel enables real-time ARDS subphenotyping with marked mortality separation. A multicenter randomized trial demonstrates methylprednisolone improves function, oxygenation, and radiology in post-COVID interstitial lung disease over 12 weeks.
Research Themes
- Precision subphenotyping and point-of-care biomarkers in ARDS
- Antifibrotic pharmacotherapy for progressive pulmonary fibrosis
- Immunomodulatory therapy in post-COVID interstitial lung disease
Selected Articles
1. Nerandomilast in progressive pulmonary fibrosis: data from the whole follow-up period of the FIBRONEER-ILD trial.
Across 1176 patients with progressive pulmonary fibrosis, nerandomilast reduced the composite risk of first acute exacerbation, respiratory hospitalization, or death over a mean 17-month observation. Benefits were more pronounced without background nintedanib, and tolerability was favorable.
Impact: This RCT follow-up shows consistent reduction in clinically meaningful outcomes—including the composite of AE-ILD, hospitalization, and death—positioning nerandomilast as a potential practice-changing antifibrotic option in PPF.
Clinical Implications: Nerandomilast could be considered as a disease-modifying therapy in PPF, especially in patients not receiving background nintedanib. Clinicians should monitor for event reduction across AE-ILD and respiratory hospitalizations while assessing long-term safety.
Key Findings
- Nerandomilast reduced the composite of first AE-ILD, respiratory hospitalization, or death (HR 0.78 for 9 mg bid; HR 0.77 for 18 mg bid vs placebo).
- Greater benefit was observed in patients not on background nintedanib (HR 0.69 and 0.65 for 9 mg and 18 mg, respectively).
- Safety and tolerability were favorable over a mean 17.0-month observation.
Methodological Strengths
- Large randomized trial population with extended follow-up and time-to-event endpoints.
- Predefined composite clinical endpoint capturing exacerbations, hospitalizations, and death.
Limitations
- This report reflects whole follow-up analyses; detailed mortality HRs were incomplete in the abstract.
- Subgroup estimates by background antifibrotic therapy were exploratory and not powered for definitive interaction testing.
Future Directions: Head-to-head and add-on trials versus established antifibrotics, longer-term safety surveillance, and biomarker-defined enrichment could refine positioning and patient selection.
BACKGROUND: In the FIBRONEER-ILD trial in patients with progressive pulmonary fibrosis (PPF), nerandomilast 9 mg bid and 18 mg bid reduced the decline in forced vital capacity at week 52 compared with placebo (the primary endpoint). We assessed the effects of nerandomilast up to the final database lock. METHODS: Time to first acute exacerbation of ILD, hospitalisation for respiratory cause, or death (key secondary endpoint) and other time-to-event endpoints were assessed. RESULTS: 1176 patients, of whom 512 were taking background nintedanib, received nerandomilast or placebo. At final database lock, mean (sd) exposure to trial medication was 15.1 (5.7) months and mean (sd) observation period was 17.0 (4.1) months. Compared with placebo, the hazard ratio (95% CI) for the key secondary endpoint was 0.78 (0.61, 1.00) for nerandomilast 9 mg bid and 0.77 (0.60, 0.99) for nerandomilast 18 mg bid; hazard ratios were lower among patients not taking nintedanib (0.69 [0.49, 0.97] and 0.65 [0.46, 0.92], respectively) than among those taking background nintedanib (0.90 [0.63, 1.30] and 0.93 [0.65, 1.34], respectively). For death, the hazard ratio (95% CI) CONCLUSIONS: In the FIBRONEER-ILD trial in patients with PPF, nerandomilast reduced the risk of clinically important outcomes, including death, over the whole trial. Nerandomilast had a favourable safety and tolerability profile.
2. Bedside identification of subphenotypes in acute respiratory failure (PHIND): a multicentre, observational cohort study.
Using a one-hour, near-patient assay for IL-6 and sTNFR1 combined with bicarbonate, the study prospectively identified hyperinflammatory and hypoinflammatory subphenotypes in ARDS/AHRF. Hyperinflammatory patients had substantially higher 60-day mortality (51% vs 28%; adjusted OR 2.7), enabling actionable risk stratification at the bedside.
Impact: This is among the first prospective, near-patient implementations of ARDS subphenotyping with clear prognostic separation, paving the way for biomarker-guided trials and precision therapeutics.
Clinical Implications: ICUs can feasibly deploy rapid IL-6/sTNFR1 testing to classify ARDS phenotype and inform trial enrollment or tailored interventions, prioritizing hyperinflammatory patients for targeted therapies as evidence emerges.
Key Findings
- Near-patient, ~1-hour IL-6/sTNFR1 plus bicarbonate testing prospectively classified ARDS/AHRF into hyper- and hypoinflammatory phenotypes.
- Hyperinflammatory patients showed markedly higher 60-day mortality (51% vs 28%; RR 1.8; adjusted OR 2.7).
- Feasibility was demonstrated across multiple centers, aligning with prior retrospective biology and supporting precision medicine approaches.
Methodological Strengths
- Prospective, multicenter design with bedside-compatible biomarker platform.
- Validated parsimonious logistic model and prespecified primary outcome (60-day mortality).
Limitations
- Observational design; no therapeutic assignment based on phenotype within the study.
- Limited racial diversity and conducted within UK/Ireland health systems, which may affect generalizability.
Future Directions: Subphenotype-stratified interventional trials (e.g., immunomodulation in hyperinflammatory ARDS), external validation in broader populations, and integration into adaptive platform trials.
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a clinically defined, biologically heterogeneous condition with no proven disease-modifying therapies. Retrospective analyses have identified two biologically distinct subphenotypes (hyperinflammatory and hypoinflammatory) of ARDS, with differing outcomes and responses to therapy. Rapid identification of these subphenotypes in an actionable timeframe has previously not been possible. The PHIND study aimed to prospectively identify these subphenotypes and to demonstrate differing 60-day mortality. METHODS: The PHIND study was a prospective, multicentre, observational cohort study conducted in intensive care units (ICUs) within the National Health Service in the UK and the Health Service Executive in Ireland. Adult patients aged 18 years and older with ARDS or acute hypoxaemic respiratory failure (AHRF) were enrolled within 72 h of onset of the syndrome. Eligible patients were required to be receiving invasive mechanical ventilation, non-invasive ventilation, or high-flow nasal oxygen. Plasma interleukin (IL-6) and soluble TNF receptor-1 (TNFR1) were quantified at enrolment using a near-patient benchtop immunoanalyser (Randox multiSTAT) with a run time of approximately 1 h. Together with plasma bicarbonate measured from an arterial blood sample, these values were used to prospectively determine subphenotypes on an individual patient basis using a validated parsimonious logistic regression model. The primary outcome was 60-day mortality. The study was registered on ClinicalTrials.gov, NCT04009330. FINDINGS: Between Nov 22, 2019, and Sept 28, 2023, 1853 patients from 30 centres were screened for eligibility. Of these, 1328 were excluded and 525 were recruited into the study, with 512 individuals included. 308 (60%) patients were male, 204 (40%) were female, and mean age was 57·0 years (SD 15·1). 443 (87%) patients were white, 18 (4%) were Black, and 16 (3%) were Asian. 490 were subphenotyped using the near-patient assay: 89 (18%) were classified as hyperinflammatory and 401 (82%) as hypoinflammatory. The primary outcome of 60-day mortality was measured in 486 patients after four patients withdrew consent for confirmation of vital status. 60-day mortality was significantly higher in the hyperinflammatory group (45 [51%] of 88) than in the hypoinflammatory group (111 [28%] of 398; risk ratio 1·8 [95% CI 1·4-2·4], p<0·0001). After adjustment, hyperinflammatory patients had increased odds of 60-day mortality (adjusted odds ratio 2·7 [95% CI 1·6-4·4], p=0·0002). INTERPRETATION: Rapid identification of ARDS inflammatory subphenotypes using a near-patient assay was feasible and associated with many clinical characteristics and outcomes consistent with those described in earlier retrospective studies, including mortality, prevalence of sepsis, and incidence of metabolic acidosis. These findings support the implementation of precision medicine approaches in ARDS and the urgent need for prospective, subphenotype-stratified interventional trials. FUNDING: Innovate UK, Randox Laboratories, and Belfast Health & Social Care Trust.
3. Methylprednisolone in the management of post-COVID-19 interstitial lung disease: A randomized trial (STERCOV-ILD).
In a multicenter randomized trial of 229 patients with post-COVID ILD, methylprednisolone for 12 weeks increased functional improvement versus supportive care and improved FVC, 6MWD, SpO2, and radiologic resolution. Smoking, older age, and severe acute COVID-19 predicted poorer outcomes.
Impact: This randomized evidence addresses a prevalent post-COVID complication and shows clinically meaningful gains in function, physiology, and imaging, informing near-term management where guidance has been limited.
Clinical Implications: For symptomatic post-COVID ILD with exertional desaturation, a time-limited methylprednisolone regimen can be considered to accelerate recovery, with monitoring for steroid adverse effects and risk stratification by age, smoking, and initial COVID-19 severity.
Key Findings
- At 12 weeks, functional improvement was higher with methylprednisolone (74.2%) than supportive care (55.2%) (OR 2.33, 95% CI 1.34–4.06).
- Greater improvements in FVC (+7.2% vs +3.7%), 6MWD (+91 vs +41 m), and SpO2 (+2.33 vs +1.21) in the steroid arm.
- Radiologic improvement occurred in 61.3% vs 46.7% (OR 1.81), and poorer outcomes were associated with smoking, older age, and severe initial COVID-19.
Methodological Strengths
- Multicenter randomized controlled design with prespecified functional, physiologic, and imaging endpoints.
- Clinically meaningful, patient-centered primary outcome tied to exertional hypoxemia resolution.
Limitations
- Short 12-week follow-up; durability of benefits and relapse rates are unknown.
- Blinding and detailed safety profiles were not fully described in the abstract.
Future Directions: Longer-term, blinded trials with taper strategies, steroid-sparing comparisons, and biomarker-guided selection are warranted to define durability and optimal candidates.
BACKGROUND AND AIM: Post-COVID-19 Interstitial Lung Disease (ILD) is controversial and need for treatment is unclear.The aim of this study was to investigate the efficacy of methylprednisolone in the management of post-COVID-19 ILD in comparison to standard of care. METHODS: In this multicentre, randomized controlled clinical trial, patients with post-COVID ILD were assigned to two groups: the steroid group received oral methylprednisolone at a dose of 0.5 mg/kg/day, while the control group received supportive therapy. The primary outcome was proportion of patients with functional improvement (defined as the absence of hypoxemia/desaturation during 6MWT) at twelve-weeks. RESULTS: A total of 229 patients with post-COVID ILD patients (124 in the steroid group and 104 in the control group) completed the study. At 12-weeks, functional improvement rate was higher in the steroid group compared to the control group (74.2% vs. 55.2%, OR:2.33 [95% CI:1.34-4.06], p=0.0041). Radiological improvement was observed in 61.3% of the steroid group compared to 46.7% of the controls (OR:1.81 [95% CI:1.07-3.06], p=0.037). The mean increase in FVC (7.2% vs 3.7%, p=0.03), 6MW distance (91 vs 41 meters, p<0.001), and SpO2 (2.33 vs 1.21, p=0.002) was significantly higher in the steroid group. Multivariate regression analysis revealed that the following variables were associated with poorer outcomes: smoking (OR:0.932 [95% CI:0.875-0.992], p=0.028), older age (OR:0.951 [95% CI:0.912-0.99], p=0.035), and severe COVID-19 (OR:0.233 [95% CI:0.068-0.799], p=0.029. CONCLUSIONS: Methylprednisolone improved oxygen saturation, FVC, exercise capacity, and radiological resolution in patients with post-COVID-19 ILD compared to the natural course of the disease.